Lentil (Lens culinaris Medik.) is a self-pollinating, diploid, annual, cool-season, meals legume crop that’s cultivated all through the world. Ascochyta blight (AB), attributable to Ascochyta lentis Vassilievsky, is an economically necessary and widespread illness of lentil. Improvement of cultivars with excessive ranges of sturdy resistance supplies an environmentally acceptable and economically possible methodology for AB management.
An in depth understanding of the genetic foundation of AB resistance is therefore extremely fascinating, with a purpose to get hold of perception into the quantity and affect of resistance genes. Genetic linkage maps primarily based on single nucleotide polymorphisms (SNP) and easy sequence repeat (SSR) markers have been developed from three recombinant inbred line (RIL) populations. The IH × NF map contained 460 loci throughout 1461.6 cM, whereas the IH × DIG map contained 329 loci throughout 1302.5 cM and the third map, NF × DIG contained 330 loci throughout 1914.1 cM.
Information from these maps had been mixed with a map from a beforehand revealed examine via use of bridging markers to generate a consensus linkage map containing 689 loci distributed throughout seven linkage teams (LGs), with a cumulative size of 2429.61 cM at a mean density of 1 marker per 3.5 cM. Trait dissection of AB resistance was carried out for the RIL populations, figuring out totals of two and three quantitative trait loci (QTLs) explaining 52 and 69% of phenotypic variation for resistance to an infection within the IH × DIG and IH × NF populations, respectively. Presence of widespread markers within the neighborhood of the AB_IH1- and AB_IH2.1/AB_IH2.2-containing areas on each maps helps the inference {that a} widespread genomic area is chargeable for conferring resistance and is related to the resistant guardian, Indianhead. The third QTL was derived from Northfield. Analysis of markers related to AB resistance throughout a various lentil germplasm panel revealed that the identification of alleles related to AB_IH1 predicted the phenotypic responses with excessive ranges of accuracy (~86%), and due to this fact have the potential to be broadly adopted in lentil breeding applications.
The provision of RIL-based maps, a consensus map, and validated markers linked to AB resistance present necessary assets for lentil enchancment.
Comparative Agronomic Efficiency and Response to Fusarium wilt of Lens culinaris × L. orientalis and L. culinaris × L. ervoides derivatives.
The event of transgressive phenotype within the segregating populations has been imagined to contribute to area of interest divergence of hybrid lineages, which happens most steadily at bigger genetic distances. Wild Lens species are thought of to be extra resistant in opposition to main biotic and abiotic stresses than that of the cultivated species. Within the current examine, we assessed the comparative agronomic efficiency of lentil (Lens culinaris subsp. culinaris) inter-sub-specific (L. culinaris subsp. orientalis) and interspecific (L. ervoides) derivatives, additionally mentioned its possible foundation of incidence.
The F3, F4, and F5 inter sub-specific and interspecific populations of ILL8006 × ILWL62 and ILL10829 × ILWL30, respectively revealed a considerable vary of variation for majority of agro-morphological traits as mirrored by the vary, imply and coefficient of variation. A excessive degree of fruitful heterosis was additionally noticed in F3 and F4 progeny for necessary traits of curiosity. Phenotypic coefficient of variation (PCV) was increased in magnitude than genotypic coefficient of variation (GCV) in all generations for a number of quantitative characters. The outcomes confirmed excessive heritability estimates for majority of traits along with low to excessive genetic advance in F3 and F4 generations. Additional, F5 progeny of ILL10829 × ILWL30, manifested resistant illness response for fifteen recombinant inbred strains (RILs) in opposition.
The multilocation agronomic analysis of each crosses confirmed higher outcomes for earliness, fascinating seed yield and Fusarium wilt resistance underneath two agro-ecological areas of north-western India.
These higher performing recombinants of ILL8006 × ILWL62 and ILL10829 × ILWL30 might be superior for additional genetic enchancment and growing excessive yielding illness resistant cultivars of lentil.
The Results of Lentivirus-mediated shRNA Interference Concentrating on Mcl-1 on Progress of NK/T-cell Lymphoma.
Myeloid leukemia-1 (Mcl-1) gene has been reported as an necessary consider varied varieties of most cancers, however little analysis was processed on pure killer (NK)/T-cell lymphoma, a form of a extremely aggressive illness with a poor prognosis. Right here we investigated the expression of Mcl-1 in seven lymphoma cell strains and its potential function as a molecular drug goal for NK/T-cell lymphoma remedy by utilizing lentivirus-mediated shRNA interference focusing on Mcl-1. In our examine, the expression of Mcl-1 in numerous lymphoma cell strains had been evaluated firstly, after that lenti-shMcl-1 was constructed and transduced into NK/T-cell lymphoma cell line SNK-6 which had a excessive degree expression of Mcl-1.
Methylthiazolete-Trazolium (MTT) assay and circulate cytometry (FCA) had been employed to detect the standing of proliferation and apoptosis after an infection. Lastly we investigated the consequences of chemotherapy agent vincristine (VCR) mixture with lenti-shMcl-1 by MTT and FCA assay. The outcomes confirmed that Mcl-1 gene expressed in all seven lymphoma cell strains at totally different ranges. Recombinant lentiviruses might infect SNK-6 cells successfully. Mcl-1 expression degree was remarkably down-regulated after an infection with lenti-shMcl-1. The expansion of SNK-6 cells was inhibited considerably via apoptosis pathway.
Ready-to-use BSA Standard Solution Set (8 different concentrations) |
|
PC0003 |
Solarbio Life Science |
8x 1 mL |
Ask for price |
Human Glucose concentration-Glucose concentration- ELISA Kit |
|
QY-E05365 |
Qayee Biotechnology |
96T |
EUR 400 |
Lentivirus Concentrator |
|
LV-CONC |
GenTarget |
one kit |
EUR 276.5 |
|
Description: lentivirus concentration kit |
Gas concentration agent |
|
nBIONIX-A07 |
Bulldog Bio |
20 |
EUR 138 |
ETHANOL, 70% CONCENTRATION |
|
IB15727 |
IBI Scientific |
10L |
EUR 210.13 |
|
Description: BOX W/SPIGOT (HAZ) |
Denhardt's solution, 100x Concentrate |
|
D0062 |
Bio Basic |
25ml |
EUR 82.97 |
|
|
PE Streptavidin (High Concentration) |
|
GT17634 |
Sony |
500 µg |
Ask for price |
|
|
APC Streptavidin (High Concentration) |
|
GT17633 |
Sony |
500 µg |
Ask for price |
|
|
Minimal Inhibitory Concentration Kit |
|
K195-2500 |
Biovision |
each |
EUR 836.4 |
Minimal Inhibitory Concentration Kit |
|
K195-500 |
Biovision |
each |
EUR 574.8 |
AvaI -HC unit: 330, High Concentration |
|
YRAVA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
SacI -HC unit: 1500, High Concentration |
|
YRSAC1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EF1a-(Red-Luciferase) Lentivirus
(Zeocin), Concentrated Lentivirus |
|
LVP1304-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Zeocin selection. |
X-Gal Solution, 40 mg/ml concentrate |
|
X0321-005 |
GenDepot |
5X1ml |
EUR 45 |
X-Gal Solution, 40 mg/ml concentrate |
|
X0321-020 |
GenDepot |
20ml |
EUR 70 |
Kpn I -HC unit: 5000, High Concentration |
|
YRKPN1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Msp I -HC unit: 1400, High Concentration |
|
YRMSP1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Nco I -HC unit: 400, High Concentration |
|
YRNCO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pst I -HC unit: 12000, High Concentration |
|
YRPST1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Pvu II -HC unit: 2000, High Concentration |
|
YRPVU2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Rsa I -HC unit: 800, High Concentration |
|
YRRSA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sal I -HC unit: 2200, High Concentration |
|
YRSAL1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Sma I -HC unit: 1500, High Concentration |
|
YRSMA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Taq I -HC unit: 410, High Concentration |
|
YRTAQ1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xba I -HC unit: 3000, High Concentration |
|
YRXBA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Xho I -HC unit: 5000, High Concentration |
|
YRXHO1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EF1a-(Red-Luciferase) Lentivirus
(Neomycin), Concentrated Lentivirus |
|
LVP1234-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Neomycin selection. |
Dra I-HC unit: 3500, High Concentration |
|
YRDRA1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR I -HC unit: 12000, High Concentration |
|
YRECOR1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Concentrating Solution for Sirius Red Total Collagen Detection Other |
|
90626 |
Chondrex |
50 ml |
EUR 14 |
|
Description: Concentrating Solution for Sirius Red Total Collagen Detection Kit |
BamH I-HC unit: 12000, High Concentration |
|
YRBAMH1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Bgl II-HC unit: 2500, High Concentration |
|
YRBGL2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoR V-HC unit: 2000, High Concentration |
|
YRECOR5-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hind III -HC unit: 12000, High Concentration |
|
YRHIND3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinf I-HC unit: 2000, High Concentration |
|
YRHINF1-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EF1a-(Red-Luciferase) Lentivirus
(Hygromycin), Concentrated Lentivirus |
|
LVP1305-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Hygromycin selection. |
EF1a-(Red-Luciferase) Lentivirus
(Puromycin), Concentrated Lentivirus |
|
LVP475-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Puromycin selection. |
ViaCheck™ Concentration Control (0.5 × 106) |
|
VC50N-20 |
Polysciences Europe GmbH |
20 mL |
EUR 247.32 |
|
Description: HS Code : 38220000 |
ViaCheck Concentration Control 1 x 106 |
|
VC60N-20 |
Bangs Laboratories |
20 ml |
EUR 251.33 |
|
Description: ViaCheck Concentration Control 1 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 4 x 106 |
|
VC70N-20 |
Bangs Laboratories |
20 ml |
EUR 367.48 |
|
Description: ViaCheck Concentration Control 4 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
ViaCheck Concentration Control 8 x 106 |
|
VC80N-20 |
Bangs Laboratories |
20 ml |
EUR 410.53 |
|
Description: ViaCheck Concentration Control 8 x 106 mimic the characteristics of live and dead cells in the trypan blue dye exclusion method and may be used to support validation and QC of image-based cell viability analyzers |
UPCK™ Urine Protein Concentration Kit |
|
UPCK-25 |
Biotech Support Group |
25 preps |
EUR 1143.6 |
|
Description: Urine Protein Enrichment Kit |
Cas9 Nuclease Protein (High Concentration) |
|
K108 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
BssH II-HC unit: 200, High Concentration |
|
YRBSSH2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
BstE II-HC unit: 1300, High Concentration |
|
YRBSTE2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
EcoT38 I -HC unit: 900, High Concentration |
|
YRECOT38-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hae III-HC unit: 3400, High Concentration |
|
YRHAE3-HC |
Yeastern Biotech |
1 vial |
Ask for price |
Hinc II-HC unit: 500, High Concentration |
|
YRHINC2-HC |
Yeastern Biotech |
1 vial |
Ask for price |
h LDOC1 (HA), Concentrated Lentivirus |
|
LVP1132-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Premade lentivirus over-express human LDOC1 gene with N-term HA tag. It contains a RFP_Blasticidin fusion dual marker. |
EF1a-(Red-Luciferase) Lentivirus
(Blasticidin), Concentrated Lentivirus |
|
LVP1232-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus in PBS express Red-Luciferease under EF1a promoter, containing Blasticidin selection. |
saCas9 Nuclease Protein (High Concentration) |
|
K144 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
h NEUROG2 Expression Lentivirus, concentrated |
|
LVP658-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated lentivirus express human target: NEUROG2 (neurogenin 2), containing RFP-Blasticidin dual selection |
m Plaur (CD87), Concentrated Lentivirus |
|
LVP1400-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: lentivirus express mouse target: Plaur (CD87), containing a RFP-Blasticidin dual selection marker. |
h IL1R1 (6His), Concentrated Lentivirus |
|
LVP1133-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Premade lentivirus over-express human IL1R1 gene with C-term 6His tag. It contains a RFP_Blasticidin fusion dual marker. |
BCA Protein concentration determination kit |
|
BC016-500ml |
ELK Biotech |
500ml |
EUR 110 |
GFP (CMV, No antibiotics) Lentivirus, Concentrated |
|
LVP1334-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated Lentivirus express GFP under CMV promoter (Does not contain any antibioic selection.) |
RFP (CMV, No antibiotics) Lentivirus, Concentrated |
|
LVP1336-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated Lentivirus express GFP under CMV promoter (Does not contain any antibioic selection.) |
mkate (CMV, Puro), Concentrated Lentivirus |
|
LVP1507-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: mKate expression lentivirus under suCMV promoter, carrying Puromycin selection |
Cas9 Null Mutant Protein (High Concentration) |
|
K140 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
GFP (EF1a, No antibiotics) Lentivirus, Concentrated |
|
LVP1335-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated Lentivirus express GFP under EF1a promoter (Does not contain any antibioic selection.) |
RFP (EF1a, No antibiotics) Lentivirus, Concentrated |
|
LVP1337-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated Lentivirus express GFP under EF1a promoter (Does not contain any antibioic selection.) |
BFP-Histone2B, Concentrated Lentivirus |
|
LVP1491-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentivirus expressing (BFP-human Histone 2B) fusion contruct under suCMV promoter without any antibiotic selection. |
Mito-GFP (Puro), Concentrated Lentivirus |
|
LVP893-G-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentiviral particles for sub-cellular fluorescent labeling, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. GFP fluorescent signal targeted in Mitochondria. It contains the Puromycin selection marker. |
Cas9 Nuclease NLS Protein (High Concentration) |
|
K130 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 80 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
Cas9 Nickase D10A Protein (High Concentration) |
|
K132 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To counteract off-target mutagenic effects of this system, the Cas9 Nickase D10A was developed with a D10A mutation in its RuvC1 nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
dNTP SET, Concentration: 100mM, 4x1ml
set of dNTP consisting 4 separate tubes (4x1ml) each with 100mM concentration of dATP, dGTP, dCTP, and dTTP. |
|
2013SET |
ACTGene |
each |
EUR 361.42 |
|
|
Myoglobin Concentration ELISA Quantitation Kit |
|
GWB-E1E945 |
GenWay Biotech |
ELISA_Kits |
Ask for price |
DsRNA-unmodified Standard (High Concentration) |
|
DD3413-C1 |
Vazyme |
50 μL |
Ask for price |
Cas9 Nickase H840A Protein (High Concentration) |
|
K136 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. One concern with the current CRISPR Cas9 technology is the potential off-target effects of the Cas9 nuclease. ;;To improve the off-target mutagenic effects of this system, the Cas9 Nickase H840A Protein was developed with a H840A mutation in its HNH-like nuclease domain. Unlike the Cas9 nuclease, this mutant form generates a single-stranded nick instead of a double-strand break (DSB). Because a single DNA nick is quickly repaired with high fidelity by the cellular machinery, the system requires two closely juxtaposed nicks in order to trigger the same genomic disruption as the Cas9 nuclease. This effectively boosts the recognition sequence to 40 instead of 20 nucleotides, and, as a result, off-target effects become highly unlikely. Thus, the double-nickase CRISPR system offers unparalleled specificity to satisfy even the most stringent of experimental requirements.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First, the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. |
saCas9 Null Mutant Protein (High Concentration) |
|
K146 |
ABM |
32.5 µg (250pmol) Volume: 25µL |
EUR 155 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The saCas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type saCas9. Such a saCas9 protein retains its ability to bind to genomic DNA through sgRNA:genomic DNA base pairing, however, the saCas9 Null Mutant does not induce cleavage. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). |
mCherry (CMV, Puro), Concentrated Lentivirus |
|
LVP1419-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: mCherry expression lentivirus under suCMV promoter, carrying Puromycin selection |
mTomato (CMV, Puro), Concentrated Lentivirus |
|
LVP1506-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: mTomato expression lentivirus under suCMV promoter, carrying Puromycin selection |
fnCpf1 Nuclease NLS Protein (High Concentration) |
|
K187 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
fnCpf1 is from the bacteria Francisella novicida. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by fnCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
asCpf1 Nuclease NLS Protein (High Concentration) |
|
K188 |
ABM |
380 μg (2.5 nmol) Volume: 250µL |
EUR 365 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases. ; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
|
K189 |
ABM |
32.5 µg (250pmol) Volume: 50µL |
EUR 155 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
asCpf1 Nuclease NLS Protein (High Concentration) |
|
K088 |
ABM |
38 μg (250 pmol) Volume: 25µL |
EUR 75 |
Description: Using Cpf1 (a.k.a. Cas12a) in your CRISPR experiment offers several advantages over other CRISPR-associated nucleases.; - Due to the T-rich PAM sequence (TTTN), Cpf1 enables editing in regions unable to be targeted by Cas9.
- Cpf1 can be used with a shorter guide RNA (called crRNA) than Cas9.
- Cpf1 creates a staggered cut in dsDNA instead of a blunt cut.
- Cpf1 cuts distal to the PAM sequence, which may allow for multiple rounds of cleavage.
asCpf1 is from the bacteria Acidaminococcus. This protein contains a SV40 T antigen nuclear localization signal (NLS) on the N-terminus of the protein. If the cut caused by asCpf1 is repaired by non-homologous end joining (NHEJ), an indel may be formed that disrupts the open reading frame of the targeted gene, leading to gene knockout. Alternatively, by supplying a repair template, a sequence can be knocked in at the cleavage site via homology directed repair (HDR).
|
saCas9 Nuclease NLS Protein (High Concentration) |
|
K089 |
ABM |
6.5 µg (50pmol) Volume: 50µL |
EUR 55 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 nuclease serves to unwind the genomic DNA duplex next to conserved protospacer adjacent motifs (PAMs) and homes in on its target sequence, which is recognized by a complementary single-guide RNA. The resulting double-stranded break gets repaired by the non-homologous end joining (NHEJ) pathway, leading to a disruption in the open reading frame of the targeted gene. Alternatively, by supplying a suitable repair template, virtually any desired point mutation can be introduced at the break point via homology-directed repair (HDR).;;The Cas9 nuclease from the bacteria Staphylococcus aureus, abbreviated saCas9, is gaining popularity as an alternative to spCas9 due to its relatively smaller size. The saCas9 PAM sequence is 5’-NNGRRN (preferably 5’-NNGRRT). saCas9 Nuclease NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
mCherry (EF1a, Puro), Concentrated Lentivirus |
|
LVP1420-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: mCherry expression lentivirus under EF1a promoter, carrying Puromycin selection |
h ACE2 (GFP-Puro) concentrated Lentivirus |
|
LVP1310-GP-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated lentivirus express human target: ACE2, containing a GFP-Puromycin dual selection marker. |
h MFN2 (GFP-Puro) Concentrated Lentivirus |
|
LVP1327-GP-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated lentivirus for human target: MFN2, containing a GFP-Puromycin dual selection marker. |
h IDO1 (GFP-Puro), Concentrated Lentivirus |
|
LVP302-GP-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated lentivirus expres a human human IDO1 with a GFP-Puromycin fusion marker. |
h CD19 (GFP-Pueo), Concentrated Lentivirus |
|
LVP1084-GP-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Over-expression lentivirus expressing human target: CD19 gene, carrying GFP-Puromycin dual selection |
h ETV2 Expression, concentrated Lentivirus |
|
LVP1369 |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: concentrated expression lentivirus for human target: ETV2, containing a RFP-Blasticidin dual selection marker. |
h MSLN Expression, Concentrated Lentivirus |
|
LVP1378-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Over-expression lentivirus for human target: MSLN, containing a RFP-Blasticidin dual selection marker. |
RFP-Actin fusion, Concentrated Lentivirus |
|
LVP446-R-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentiviral particles expressing (RFP-human Actin) fusion contruct under suCMV promoter, provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
h YAP1 Expression, Concentrated Lentivirus |
|
LVP478-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentivirus express human target: YAP1 (alternative name: YAP, YAP2, YAP65, YKI), containing a RFP-Blasticidin dual selection marker. |
h BMP2 Expression, Concentrated Lentivirus |
|
LVP481-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made express human target: BMP2 gene, carrying RFP-Blasticidin dual selection. |
h BCL2 Expression, Concentrated lentivirus |
|
LVP553-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made Lentivirus express human target: h BCL2, containing a RFP-Blasticidin dual selection marker. |
h GRM2 Expression, Concentrated Lentivirus |
|
LVP660-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for expressing human target: GRM2 (glutamate receptor, metabotropic 2), contains the RFP-Blasticidin dual selection marker. |
h IL10 Expression, Concentrated Lentivirus |
|
LVP767 |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated lentivirus for expressing human target: h IL10 (interleukin 10), containing a RFP-Blasticidin dual selection marker. |
h SOX9 Expression, Concentrated Lentivirus |
|
LVP773-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for expressing human target: SOX9 (SRY (sex determining region Y)-box 9), [alternative names: CMD1; CMPD1; SRA1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_000346_3. It also contains a RFP-Blasticidin dual selection marker. |
h Mafa Expression, Concentrated Lentivirus |
|
LVP794-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentivirus express human target: h Mafa. It contains a RFP-Blasticidin dual selection marker. |
h CD40 Expression, Concentrated Lentivirus |
|
LVP888-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: expression lentivirus express human target: CD40 (CD40 molecule, TNF receptor superfamily member 5), containg a RFP-Blasticidin dual selection marker. |
h DLL1 Expression, Concentrated Lentivirus |
|
LVP907 |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made lentivirus express human target: h DLL1. It contains a RFP-Blasticidin dual selection marker. |
h CD47 Expression, Concentrated Lentivirus |
|
LVP918-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated expression lentivirus for human target: CD47, containing a RFP-Blasticidin dual selection marker. |
h TERT Expression, Concentrated Lentivirus |
|
LVP105-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated Lentivirus express human TERT gene with a Blasticidin-RFP fusion marker (Dual selection). |
h CD19 Expression, Concentrated Lentivirus |
|
LVP1084-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Concentrated lentivirus express human target: CD19 (human CD19 molecule). It contains a RFP-Blasticidin dual selection marker. |
h EGFR Expression, Concentrated Lentivirus |
|
LVP1142-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for human target: EGFR, containing a RFP-Blasticidin dual selection marker. |
h CD8a Expression, Concentrated Lentivirus |
|
LVP1151-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for human target: CD8a, containing a RFP-Blasticidin dual selection marker. |
h NEK6 Expression, Concentrated Lentivirus |
|
LVP1182-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for human target: NEK6, containing a RFP-Blasticidin dual selection marker. |
h STM1 Expression, Concentrated Lentivirus |
|
LVP1209-PBS |
GenTarget |
1x10^8 IFU/ml x 200ul |
EUR 455 |
|
Description: Pre-made over-expression lentivirus for human target: STM1, containing a RFP-Blasticidin dual selection marker. |
Cas9 Null Mutant NLS Protein (High Concentration) |
|
K142 |
ABM |
40 µg (250pmol) Volume: 25µL |
EUR 135 |
|
Description: The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is the latest RNA-guided, endonuclease tool in genome editing which allows for very specific genomic disruption and replacement. ;;The Cas9 Null Mutant Protein is created by mutating both cleavage domains of the wild type Cas9 (D10A and H840A). Such a Cas9 protein retains its ability to bind to genomic DNA through gRNA:genomic DNA base pairing, however, unlike Cas9 Nuclease and Cas9 Nickase, where permanent gene disruption can be achieved, the Cas9 Null Mutant does not introduce any genome modifications. Therefore, this protein can provide a useful negative control for CRISPR experiments. In addition, binding of the Null Mutant can act as a roadblock to hinder transcription, thus offering a useful tool to achieve reversible knock-down of gene expression.;;The Cas9 nuclease from the bacteria Streptococcus pyogenes, abbreviated spCas9, is the most commonly used Cas9 variant. The reason for spCas9 popularity is two-fold. First the spCas9 PAM sequence is 5’-NGG, which is highly abundant in the genome allowing virtually any gene to be targeted. The spCas9 enzyme also has on average a higher efficiency in vivo compared to other variants. Cas9 Null Mutant NLS contains a SV40 T antigen nuclear localization sequence (NLS) on the C-terminus of the protein. |
In any other case, lenti-shMcl-1 additionally revealed a big chemosensitizing impact together with vincristine. In a phrase, we demonstrated that lenti-shMcl-1 had a big anti-NK/T cell lymphoma impact and focusing on Mcl-1 remedy could possibly be a promising novel method in remedy of lymphoma.